Published in J Control Release on December 03, 2012
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv Drug Deliv Rev (2015) 1.08
Surface engineering of liposomes for stealth behavior. Pharmaceutics (2013) 0.90
Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.88
Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity. Proc Natl Acad Sci U S A (2015) 0.84
Hepatic RNA Interference: Delivery by Synthetic Vectors. Drug Deliv Transl Res (2014) 0.77
Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. J Control Release (2015) 0.76
Mechanistic study on the ABC phenomenon of PEG conjugates. J Control Release (2013) 0.75
Micellar emulsions composed of mPEG-PCL/MCT as novel nanocarriers for systemic delivery of genistein: a comparative study with micelles. Int J Nanomedicine (2015) 0.75
Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. ACS Appl Mater Interfaces (2016) 0.75
Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature (2006) 22.65
IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol (2005) 18.32
Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol (2004) 5.71
Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat Immunol (2008) 5.10
Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med (2006) 5.01
Detection of pathogenic intestinal bacteria by Toll-like receptor 5 on intestinal CD11c+ lamina propria cells. Nat Immunol (2006) 4.15
Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol (2006) 4.01
The Atg5 Atg12 conjugate associates with innate antiviral immune responses. Proc Natl Acad Sci U S A (2007) 3.93
Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med (2005) 3.85
Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol (2007) 3.14
Cutting edge: TREM-2 attenuates macrophage activation. J Immunol (2006) 3.07
A host type I interferon response is induced by cytosolic sensing of the bacterial second messenger cyclic-di-GMP. J Exp Med (2009) 2.92
Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med (2005) 2.90
Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol (2012) 2.48
DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med (2011) 2.41
Immunogenicity of whole-parasite vaccines against Plasmodium falciparum involves malarial hemozoin and host TLR9. Cell Host Microbe (2010) 2.03
CD8α(+) dendritic cells are an obligate cellular entry point for productive infection by Listeria monocytogenes. Immunity (2011) 1.99
Macrophage colony-stimulating factor induces the proliferation and survival of macrophages via a pathway involving DAP12 and beta-catenin. Nat Immunol (2009) 1.88
Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses. J Immunol (2008) 1.86
Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J Immunol (2003) 1.84
Contribution of IL-33-activated type II innate lymphoid cells to pulmonary eosinophilia in intestinal nematode-infected mice. Proc Natl Acad Sci U S A (2012) 1.74
Pathological role of Toll-like receptor signaling in cerebral malaria. Int Immunol (2006) 1.66
Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. Immunity (2011) 1.65
Innate immune response to viral infection. Cytokine (2008) 1.63
Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano (2012) 1.62
Cutting Edge: Pivotal function of Ubc13 in thymocyte TCR signaling. J Immunol (2006) 1.60
Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol (2002) 1.48
Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci Transl Med (2010) 1.46
Toll-like receptor 9 signaling activates NF-kappaB through IFN regulatory factor-8/IFN consensus sequence binding protein in dendritic cells. J Immunol (2004) 1.45
Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin Immunol (2004) 1.44
DNA damage sensor MRE11 recognizes cytosolic double-stranded DNA and induces type I interferon by regulating STING trafficking. Proc Natl Acad Sci U S A (2013) 1.41
Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum (2005) 1.40
Transcriptional regulation of the human TLR9 gene. J Immunol (2004) 1.38
TRAF4 acts as a silencer in TLR-mediated signaling through the association with TRAF6 and TRIF. Eur J Immunol (2005) 1.36
Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology (2002) 1.32
A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol (2011) 1.30
NLRP4 negatively regulates autophagic processes through an association with beclin1. J Immunol (2011) 1.29
Superior penetration and retention behavior of 50 nm gold nanoparticles in tumors. Cancer Res (2012) 1.29
Malaria parasites require TLR9 signaling for immune evasion by activating regulatory T cells. J Immunol (2008) 1.23
A critical role of IL-33 in experimental allergic rhinitis. J Allergy Clin Immunol (2012) 1.18
Effect of suppressive DNA on CpG-induced immune activation. J Immunol (2002) 1.16
Enhanced TLR-mediated NF-IL6 dependent gene expression by Trib1 deficiency. J Exp Med (2007) 1.16
Innate and adaptive immune responses to viral infection and vaccination. Curr Opin Virol (2011) 1.15
Manipulation of host innate immune responses by the malaria parasite. Trends Microbiol (2007) 1.14
Gold nanoparticles functionalized with therapeutic and targeted peptides for cancer treatment. Biomaterials (2011) 1.14
Purified malaria pigment (hemozoin) enhances dendritic cell maturation and modulates the isotype of antibodies induced by a DNA vaccine. Infect Immun (2002) 1.13
Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther (2011) 1.12
Th1-like cytokine induction by heat-killed Brucella abortus is dependent on triggering of TLR9. J Immunol (2005) 1.11
CpG oligodeoxynucleotides enhance neonatal resistance to Listeria infection. J Immunol (2005) 1.08
Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum (2002) 1.08
Suppressive oligonucleotides protect against collagen-induced arthritis in mice. Arthritis Rheum (2004) 1.06
Baculovirus induces type I interferon production through toll-like receptor-dependent and -independent pathways in a cell-type-specific manner. J Virol (2009) 1.05
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer (2008) 1.04
Experimental cerebral malaria progresses independently of the Nlrp3 inflammasome. Eur J Immunol (2010) 1.04
Design of folate-linked liposomal doxorubicin to its antitumor effect in mice. Clin Cancer Res (2008) 1.04
Effect of polyethylene glycol linker chain length of folate-linked microemulsions loading aclacinomycin A on targeting ability and antitumor effect in vitro and in vivo. Clin Cancer Res (2005) 1.03
CpG RNA: identification of novel single-stranded RNA that stimulates human CD14+CD11c+ monocytes. J Immunol (2005) 1.03
Evidence for the critical role of interleukin-12 but not interferon-gamma in the pathogenesis of experimental colitis in mice. J Gastroenterol Hepatol (2003) 1.02
Recognition of damage-associated molecular patterns related to nucleic acids during inflammation and vaccination. Front Cell Infect Microbiol (2013) 1.01
Preparation and characterization of superparamagnetic iron oxide nanoparticles stabilized by alginate. Int J Pharm (2006) 1.00
Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum (2003) 1.00
A polymeric micelle MRI contrast agent with changeable relaxivity. J Control Release (2006) 1.00
Process design for efficient and controlled drug incorporation into polymeric micelle carrier systems. J Control Release (2002) 0.99
Evidences of protection against blood-stage infection of Plasmodium falciparum by the novel protein vaccine SE36. Parasitol Int (2010) 0.98
Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist. Proc Natl Acad Sci U S A (2014) 0.98
Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol (2006) 0.97
Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase. Cancer Gene Ther (2005) 0.97
Molecular design of biodegradable polymeric micelles for temperature-responsive drug release. J Control Release (2006) 0.97
Blocking of the TLR5 activation domain hampers protective potential of flagellin DNA vaccine. J Immunol (2007) 0.96
Induction of type I interferon by adenovirus-encoded small RNAs. Proc Natl Acad Sci U S A (2010) 0.95
Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release (2006) 0.95
Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res (2004) 0.94
In vivo antitumor activity of camptothecin incorporated in liposomes formulated with an artificial lipid and human serum albumin. J Control Release (2008) 0.94
Particulate adjuvant and innate immunity: past achievements, present findings, and future prospects. Int Rev Immunol (2013) 0.94
Selective delivery of folate-PEG-linked, nanoemulsion-loaded aclacinomycin A to KB nasopharyngeal cells and xenograft: effect of chain length and amount of folate-PEG linker. J Drug Target (2008) 0.94
Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm (2008) 0.94
Serologic markers in relation to parasite exposure history help to estimate transmission dynamics of Plasmodium vivax. PLoS One (2011) 0.93
Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm (2006) 0.93
Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Lett (2013) 0.92
Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm (2008) 0.92
Folate-linked lipid-based nanoparticle for targeted gene delivery. Curr Drug Deliv (2005) 0.92
The malarial metabolite hemozoin and its potential use as a vaccine adjuvant. Allergol Int (2010) 0.92
Fragments of genomic DNA released by injured cells activate innate immunity and suppress endocrine function in the thyroid. Endocrinology (2011) 0.92
Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun (2004) 0.92
Superparamagnetic iron oxide nanoparticles stabilized by alginate: pharmacokinetics, tissue distribution, and applications in detecting liver cancers. Int J Pharm (2007) 0.92
Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm Res (2004) 0.92